

# ESMO PRECEPTORSHIP PROGRAMME GASTRIC CANCER

Multidisciplinary management, standards of care, therapeutic targets and future perspectives

Valencia, Spain 16-17 October 2020

CO-CHAIRS: Andrés Cervantes, Spain

Florian Lordick, Germany

SPEAKERS: William Allum, United Kingdom

Fatima Carneiro, Portugal Karin Haustermans, Belgium Javier Sempere, Spain

Elizabeth Smyth, United Kingdom

#### **LEARNING OBJECTIVES**

- To learn about the fundamentals of epidemiology, aetiology, pathogenesis, molecular events and ethnic patterns as contributing factors to heterogeneity in gastric cancer
- To understand the essentials in the diagnosis and multidisciplinary treatment of gastric cancer
- To learn about advances in the treatment and novel targets in gastric cancer

### Friday, 16 October 2020

| 09:00-09:10<br>10' | Opening and welcome                |   |
|--------------------|------------------------------------|---|
| 10'                | Welcome from ESMO and introduction | Andrés Cervantes, ES<br>Florian Lordick, DE |

| 09:10-11:25<br>135' | SESSION 1 Epidemiology, pathology and endoscopy of gastric cancer                        |                      |
|---------------------|--|----------------------|
| 30'                 | Epidemiology (including GE junction tumours) and clinical presentation                   | Andrés Cervantes, ES |
| 60'                 | Pathology and carcinogenesis and its potential clinical impact                           | Fatima Carneiro, PT  |
| 30'                 | Endoscopy in gastric cancer: New imaging techniques, new treatment modalities (EMR, ESD) | Javier Sempere, ES   |
| 15'                 | Discussion   | Faculty              |

| 11:25-11:55 | Coffee break |
|-------------|--------------|
|-------------|--------------|

| 11:55-13:25<br>90' | SESSION 2<br>Surgical, adjuvant and neoadjuvant treatment of gastric cancer                        |                       |
|--------------------|--|-----------------------|
| 30'                | Surgery for gastric and GE junction cancer, primary, palliative - where and when?                  | William Allum, UK     |
| 25'                | Neo- and adjuvant treatment for gastric cancer and GE junction cancer:<br>The role of radiotherapy | Karin Haustermans, BE |
| 25'                | Neo- and adjuvant treatment for gastric cancer: The role of chemotherapy                           | Elizabeth Smyth, UK   |
| 10'                | Discussion   | Faculty               |

#### 13:25-14:30 Lunch

| 14:30-15:10<br>40' | SESSION 3<br>Clinical discussions                                |                     |
|--------------------|--|---------------------|
| 30'                | Clinical case on sequential treatment of advanced gastric cancer | Florian Lordick, DE |
| 10'                | Discussion   | Faculty             |

#### 15:10-15:30 Coffee break

| 15:30-17:30<br>120' | SESSION 4<br>Advanced disease   |                      |
|---------------------|---------------------------------|----------------------|
| 30'                 | Chemotherapy                    | Andrés Cervantes, ES |
| 40'                 | Biologically targeted treatment | Florian Lordick, DE  |
| 40'                 | Immunotherapy                   | Elizabeth Smyth, UK  |
| 10'                 | Discussion                      | Faculty              |

#### 20:30 Dinner

## Saturday, 17 October 2020

| 09:00-10:30<br>90' | SESSION 5 Case discussion based on ESMO Clinical Practice Guidelines I  |                      |
|--------------------|---|----------------------|
| 6x15'              | 6 x Participants clinical case discussion                               | Faculty              |
| 10:30-11:00        | Coffee break  |                      |
| 11:00-12:30<br>90' | SESSION 6 Case discussion based on ESMO Clinical Practice Guidelines II |                      |
| 6x15'              | 6 x Participants clinical case discussion                               | Faculty              |
| 12:30-12:50<br>20' | Future outlook, conclusion and farewell                                 | Andrés Cervantes, ES |
|                    |   |                      |

Note: Each 15-minute slot for clinical case discussion includes 7' case presentation and 8' Q&A / panel discussion